FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035140149> ?p ?o ?g. }

• W3035140149 endingPage "100153" @default.
• W3035140149 startingPage "100153" @default.
• W3035140149 abstract "Background Recently, the Antenatal Late Preterm Steroids study reported that antenatal corticosteroids administered in the late preterm period (34.0–36.6 weeks’ gestation) reduced the rate of neonatal respiratory complications at birth. The utility of this intervention in women with fetal growth restriction remains unclear. Objective This study aimed to determine whether administration of antenatal corticosteroids in the late preterm period in pregnancies with growth restriction decreased the need for respiratory support at delivery and other neonatal morbidities. Study Design This was a single-center retrospective cohort study that included growth-restricted pregnancies delivered in the late preterm period. Growth restriction was defined as either a diagnosis of fetal growth restriction or small for gestational age by birthweight less than 10%. The primary composite outcome consisted of any 1 of the following occurring in a single neonate: requirement of continuous positive airway pressure or high-flow nasal cannula for 2 hours or more, oxygen requirement with fraction of inspired oxygen of ≥30% for 4 hours or more, mechanical ventilation at any time, stillbirth, or neonatal death. The primary outcome was compared between steroid naive pregnancies and pregnancies exposed to betamethasone in the late preterm period. Univariable and multivariable statistical analysis was performed and P<.05 was considered statistically significant. Results A total of 247 women with a diagnosis of growth restriction or small for gestational age met all inclusion criteria, 111 of whom did not receive antenatal corticosteroids and 136 received late preterm antenatal corticosteroids. Demographics were similar between the groups, with the exception of those who received betamethasone being more likely to be nulliparous (P=.01) and to receive a diagnosis of preeclampsia (P=.001). The primary outcome did not differ between the 2 groups (16.2% [18/111] vs 12.5% [17/136]; P=.41). Multivariable modeling controlling for parity and preeclampsia indicated that the rate of the primary composite respiratory outcome was similar between the exposure groups (adjusted odds ratio, 0.63; P=.29). Neonatal hypoglycemia (<40 mg/dL) was more common in newborns exposed to steroids (25.2% [28 /111] vs 40.4% [55/136]; P=.012). Conclusion Administration of antenatal corticosteroids in the late preterm period for pregnancies with growth restriction did not significantly decrease the need for respiratory support in newborns at our institution. The rate of neonatal hypoglycemia increased after exposure to antenatal corticosteroids. This special population may not benefit from late preterm steroids. Recently, the Antenatal Late Preterm Steroids study reported that antenatal corticosteroids administered in the late preterm period (34.0–36.6 weeks’ gestation) reduced the rate of neonatal respiratory complications at birth. The utility of this intervention in women with fetal growth restriction remains unclear. This study aimed to determine whether administration of antenatal corticosteroids in the late preterm period in pregnancies with growth restriction decreased the need for respiratory support at delivery and other neonatal morbidities. This was a single-center retrospective cohort study that included growth-restricted pregnancies delivered in the late preterm period. Growth restriction was defined as either a diagnosis of fetal growth restriction or small for gestational age by birthweight less than 10%. The primary composite outcome consisted of any 1 of the following occurring in a single neonate: requirement of continuous positive airway pressure or high-flow nasal cannula for 2 hours or more, oxygen requirement with fraction of inspired oxygen of ≥30% for 4 hours or more, mechanical ventilation at any time, stillbirth, or neonatal death. The primary outcome was compared between steroid naive pregnancies and pregnancies exposed to betamethasone in the late preterm period. Univariable and multivariable statistical analysis was performed and P<.05 was considered statistically significant. A total of 247 women with a diagnosis of growth restriction or small for gestational age met all inclusion criteria, 111 of whom did not receive antenatal corticosteroids and 136 received late preterm antenatal corticosteroids. Demographics were similar between the groups, with the exception of those who received betamethasone being more likely to be nulliparous (P=.01) and to receive a diagnosis of preeclampsia (P=.001). The primary outcome did not differ between the 2 groups (16.2% [18/111] vs 12.5% [17/136]; P=.41). Multivariable modeling controlling for parity and preeclampsia indicated that the rate of the primary composite respiratory outcome was similar between the exposure groups (adjusted odds ratio, 0.63; P=.29). Neonatal hypoglycemia (<40 mg/dL) was more common in newborns exposed to steroids (25.2% [28 /111] vs 40.4% [55/136]; P=.012). Administration of antenatal corticosteroids in the late preterm period for pregnancies with growth restriction did not significantly decrease the need for respiratory support in newborns at our institution. The rate of neonatal hypoglycemia increased after exposure to antenatal corticosteroids. This special population may not benefit from late preterm steroids." @default.
• W3035140149 created "2020-06-19" @default.
• W3035140149 creator A5012999532 @default.
• W3035140149 creator A5027421858 @default.
• W3035140149 creator A5057040843 @default.
• W3035140149 creator A5062081331 @default.
• W3035140149 date "2020-08-01" @default.
• W3035140149 modified "2023-10-13" @default.
• W3035140149 title "Antenatal corticosteroids in the late preterm period for growth-restricted pregnancies" @default.
• W3035140149 cites W2044669700 @default.
• W3035140149 cites W2118727855 @default.
• W3035140149 cites W2256097753 @default.
• W3035140149 cites W2321364247 @default.
• W3035140149 cites W2794034096 @default.
• W3035140149 cites W4234794804 @default.
• W3035140149 cites W4238199701 @default.
• W3035140149 doi "https://doi.org/10.1016/j.ajogmf.2020.100153" @default.
• W3035140149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33345883" @default.
• W3035140149 hasPublicationYear "2020" @default.
• W3035140149 type Work @default.
• W3035140149 sameAs 3035140149 @default.
• W3035140149 citedByCount "3" @default.
• W3035140149 countsByYear W30351401492023 @default.
• W3035140149 crossrefType "journal-article" @default.
• W3035140149 hasAuthorship W3035140149A5012999532 @default.
• W3035140149 hasAuthorship W3035140149A5027421858 @default.
• W3035140149 hasAuthorship W3035140149A5057040843 @default.
• W3035140149 hasAuthorship W3035140149A5062081331 @default.
• W3035140149 hasConcept C126322002 @default.
• W3035140149 hasConcept C131872663 @default.
• W3035140149 hasConcept C187212893 @default.
• W3035140149 hasConcept C2776006263 @default.
• W3035140149 hasConcept C2777080012 @default.
• W3035140149 hasConcept C2778376644 @default.
• W3035140149 hasConcept C2778780700 @default.
• W3035140149 hasConcept C2779234561 @default.
• W3035140149 hasConcept C2779547634 @default.
• W3035140149 hasConcept C2779606379 @default.
• W3035140149 hasConcept C2780807750 @default.
• W3035140149 hasConcept C2781162121 @default.
• W3035140149 hasConcept C42219234 @default.
• W3035140149 hasConcept C46973012 @default.
• W3035140149 hasConcept C54355233 @default.
• W3035140149 hasConcept C71924100 @default.
• W3035140149 hasConcept C86803240 @default.
• W3035140149 hasConceptScore W3035140149C126322002 @default.
• W3035140149 hasConceptScore W3035140149C131872663 @default.
• W3035140149 hasConceptScore W3035140149C187212893 @default.
• W3035140149 hasConceptScore W3035140149C2776006263 @default.
• W3035140149 hasConceptScore W3035140149C2777080012 @default.
• W3035140149 hasConceptScore W3035140149C2778376644 @default.
• W3035140149 hasConceptScore W3035140149C2778780700 @default.
• W3035140149 hasConceptScore W3035140149C2779234561 @default.
• W3035140149 hasConceptScore W3035140149C2779547634 @default.
• W3035140149 hasConceptScore W3035140149C2779606379 @default.
• W3035140149 hasConceptScore W3035140149C2780807750 @default.
• W3035140149 hasConceptScore W3035140149C2781162121 @default.
• W3035140149 hasConceptScore W3035140149C42219234 @default.
• W3035140149 hasConceptScore W3035140149C46973012 @default.
• W3035140149 hasConceptScore W3035140149C54355233 @default.
• W3035140149 hasConceptScore W3035140149C71924100 @default.
• W3035140149 hasConceptScore W3035140149C86803240 @default.
• W3035140149 hasIssue "3" @default.
• W3035140149 hasLocation W30351401491 @default.
• W3035140149 hasOpenAccess W3035140149 @default.
• W3035140149 hasPrimaryLocation W30351401491 @default.
• W3035140149 hasRelatedWork W1977319915 @default.
• W3035140149 hasRelatedWork W1980650874 @default.
• W3035140149 hasRelatedWork W2004795895 @default.
• W3035140149 hasRelatedWork W2049942691 @default.
• W3035140149 hasRelatedWork W2056579555 @default.
• W3035140149 hasRelatedWork W2065775597 @default.
• W3035140149 hasRelatedWork W2069368572 @default.
• W3035140149 hasRelatedWork W2119315831 @default.
• W3035140149 hasRelatedWork W2328440744 @default.
• W3035140149 hasRelatedWork W3027683983 @default.
• W3035140149 hasVolume "2" @default.
• W3035140149 isParatext "false" @default.
• W3035140149 isRetracted "false" @default.
• W3035140149 magId "3035140149" @default.
• W3035140149 workType "article" @default.